Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam
Open Access
- 29 May 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (9) , 2618-2626
Abstract
The combination of aztreonam/avibactam has promising activity against MDR Gram-negative pathogens producing metallo-β-lactamases (MBLs), such as New Delhi MBL-1. Pharmacokinetic (PK)/pharmacodynamic (PD) understanding of this combination is critical for optimal clinical dose selection. This study focuses on the determination of an integrated PK/PD approach for aztreonam/avibactam across multiple clinical Enterobacteriaceae strains. Six clinical Enterobacteriaceae isolates expressing MBLs and ESBLs were studied in an in vitro hollow-fibre infection model (HFIM) using various dosing regimens simulating human-like PK for aztreonam/avibactam. The neutropenic murine thigh infection model was used for in vivo validation against two bacterial strains. MIC values of aztreonam/avibactam for the isolates ranged from 0.125 to 8 mg/L. Using a constant infusion of avibactam at 4 mg/L, the aztreonam PK/PD index was observed as % fT>MIC. Studies performed in the presence of a fixed dose of aztreonam revealed that the efficacy of avibactam correlates best with percentage of time above a critical threshold concentration of 2–2.5 mg/L. These conclusions translated well to the efficacy observed in the murine thigh model, demonstrating in vivo validation of the in vitro PK/PD target. PK/PD evaluations for aztreonam/avibactam in HFIM yielded a single target across strains with a wide MIC range. This integrated approach could be easily applied for forecasting clinically efficacious doses for β-lactam/β-lactamase inhibitor combinations.Keywords
Funding Information
- AstraZeneca
This publication has 30 references indexed in Scilit:
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with CeftolozaneAntimicrobial Agents and Chemotherapy, 2013
- Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-LactamasesAntimicrobial Agents and Chemotherapy, 2012
- The emerging NDM carbapenemasesTrends in Microbiology, 2011
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitorsCurrent Opinion in Microbiology, 2011
- Metallo-β-lactamases: a last frontier for β-lactams?The Lancet Infectious Diseases, 2011
- Does broad-spectrum -lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?Journal of Antimicrobial Chemotherapy, 2011
- New Delhi metallo-beta-lactamase 1–producing Enterobacteriaceae: emergence and response in EuropeEurosurveillance, 2010
- Characterization of a New Metallo-β-Lactamase Gene, bla NDM-1 , and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from IndiaAntimicrobial Agents and Chemotherapy, 2009
- Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistanceAntimicrobial Agents and Chemotherapy, 1987
- AztreonamDrugs, 1986